Diffuse and focal fibrosis in patients with cardiovascular disorders Circulatory System
Conditions
Interventions
Patients are scanned once to assess possible focal or diffuse fibrosis using quantitative imaging techniques in cardiac MRI. Blood analysis is carried out before the MRI scan to measure NTproBnP, high
Sponsors
Charité
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed consent 2. Age at least 18 years (no upper limit) 3. For patients: previously detected pathology on MRI including: ischemic heart disease (acute, subacute and chronic stages), rheumatological disorders with cardiac manifestations, aortic stenosis, hypertrophic cardiomyopathy 4. For healthy volunteers: absence of cardiac, pulmonary, renal or systemic disorders
Exclusion criteria
Exclusion criteria: 1. Any contraindication for MRI 2. Chronic renal failure (glomerular filtration rate <30ml/min) 3. Previous participation in this study 4. Known allergy against MRI contrast agent 5. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial T1 and T2 times, measured using novel and reference parametric mapping techniques once during the CMR scan (single timepoint) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Detection and size of myocardial fibrosis using late gadolinium enhancement techniques and extracellular volume (ECV) by applying CMR once (single timepoint) 2. Time for each acquisition and per slice measured using the DICOM tags after images are obtained | — |
Countries
Germany
Outcome results
None listed